BioPharmSignal logoBioPharmSignal

Biotech News

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Structure Therapeutics (GPCR)Structure TherapeuticsCompany update

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two

Open original release

Related news

GPCRStructure Therapeutics2026-04-27 20:05 EST

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

GPCRStructure Therapeutics2026-04-14 20:05 EST

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

NRIXNurix Therapeutics2026-05-13 11:00 EST

Nurix Therapeutics to Participate in Upcoming Investor Conferences

KYMRKymera2026-05-06 11:00 EST

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

KNSAKiniksa2026-05-29 20:01 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

ARGXArgenx2026-05-27 05:00 EST

argenx to Present at Upcoming Investor Conferences

ATYRaTyr Pharma2026-05-13 20:01 EST

aTyr Pharma to Participate in Upcoming Investor Conferences

NRIXNurix Therapeutics2026-04-07 11:00 EST

Nurix Therapeutics to Participate in Upcoming Investor Conference

CLDXCelldex Therapeutics2026-04-13 20:01 EST

Celldex to Present at Upcoming Investor Conference

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

View all latest news

Structure Therapeutics

Structure Therapeutics is a GPCR-focused company developing oral small-molecule therapies for metabolic and inflammatory diseases. Its platform aims to combine validated biology with convenient dosing.

Recent company news

GPCRStructure Therapeutics2026-05-26 20:05 EST

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-04-27 20:05 EST

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

GPCRStructure Therapeutics2026-04-14 20:05 EST

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

GPCRStructure Therapeutics2026-03-16 11:00 EST

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Stock data

Close
48.69 USD
Market cap
2.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States